Real-Life Effectiveness of MP-AzeFlu (Dymista®) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale.

IF 2.3 Q2 MEDICINE, GENERAL & INTERNAL Pragmatic and Observational Research Pub Date : 2023-01-01 DOI:10.2147/POR.S375403
Pär Stjärne, Duc Tung Nguyen, Hans Christian Kuhl
{"title":"Real-Life Effectiveness of MP-AzeFlu (Dymista<sup>®</sup>) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale.","authors":"Pär Stjärne,&nbsp;Duc Tung Nguyen,&nbsp;Hans Christian Kuhl","doi":"10.2147/POR.S375403","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many allergic rhinitis (AR) patients have moderate/severe persistent disease. MP-AzeFlu (Dymista<sup>®</sup>) comprises intranasal azelastine hydrochloride and fluticasone propionate in a novel formulation delivered in a single device.</p><p><strong>Objective: </strong>This prospective, noninterventional study assessed the effectiveness of MP-AzeFlu (one spray/nostril twice daily; azelastine hydrochloride = 548 μg; fluticasone propionate = 200 μg) on relieving AR symptom severity.</p><p><strong>Methods: </strong>A visual analogue scale (VAS; 0 mm [not at all bothersome] to 100 mm [very bothersome]) was used during a 42-day MP-AzeFlu treatment period by 161 persistent AR (PER) patients in routine clinical practice in Sweden. Patients also assessed their sleep quality.</p><p><strong>Results: </strong>VAS scores decreased from baseline during the treatment period and patients achieved a clinically relevant VAS score cutoff before Day 7, with 89.3% reporting well or partly controlled symptoms on Day 1. VAS score decreased from 61.4 ± 22.4 mm (baseline) to 32.1 ± 24.6 mm on Day 28 and 26.1 ± 24.3 mm on Day 42 (both <i>p</i> < 0.0001), an overall reduction from baseline on Day 42 of 38.1 ± 28.2 mm. The percentage of patients with very good/good sleep quality increased from 3.7%/28.6% on Day 0 to 16.5%/51.5% on Day 42.</p><p><strong>Conclusion: </strong>MP-AzeFlu provides effective, rapid control of PER assessed by VAS in a real-world clinical setting in Sweden. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved sleep quality. MP-AzeFlu significantly improved the QoL of the patients and was well tolerated.</p>","PeriodicalId":20399,"journal":{"name":"Pragmatic and Observational Research","volume":"14 ","pages":"1-11"},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/0f/por-14-1.PMC9826638.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pragmatic and Observational Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/POR.S375403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Many allergic rhinitis (AR) patients have moderate/severe persistent disease. MP-AzeFlu (Dymista®) comprises intranasal azelastine hydrochloride and fluticasone propionate in a novel formulation delivered in a single device.

Objective: This prospective, noninterventional study assessed the effectiveness of MP-AzeFlu (one spray/nostril twice daily; azelastine hydrochloride = 548 μg; fluticasone propionate = 200 μg) on relieving AR symptom severity.

Methods: A visual analogue scale (VAS; 0 mm [not at all bothersome] to 100 mm [very bothersome]) was used during a 42-day MP-AzeFlu treatment period by 161 persistent AR (PER) patients in routine clinical practice in Sweden. Patients also assessed their sleep quality.

Results: VAS scores decreased from baseline during the treatment period and patients achieved a clinically relevant VAS score cutoff before Day 7, with 89.3% reporting well or partly controlled symptoms on Day 1. VAS score decreased from 61.4 ± 22.4 mm (baseline) to 32.1 ± 24.6 mm on Day 28 and 26.1 ± 24.3 mm on Day 42 (both p < 0.0001), an overall reduction from baseline on Day 42 of 38.1 ± 28.2 mm. The percentage of patients with very good/good sleep quality increased from 3.7%/28.6% on Day 0 to 16.5%/51.5% on Day 42.

Conclusion: MP-AzeFlu provides effective, rapid control of PER assessed by VAS in a real-world clinical setting in Sweden. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved sleep quality. MP-AzeFlu significantly improved the QoL of the patients and was well tolerated.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MP-AzeFlu (Dymista®)在瑞典持续性变应性鼻炎患者中的实际疗效:通过视觉模拟量表评估
背景:许多变应性鼻炎(AR)患者具有中/重度持续性疾病。MP-AzeFlu (Dymista®)由鼻用盐酸氮唑elastine和丙酸氟替卡松组成,是一种通过单一装置递送的新型制剂。目的:这项前瞻性、非介入性研究评估了MP-AzeFlu的有效性(每日两次,每次喷鼻;盐酸氮扎elastine = 548 μg;丙酸氟替卡松= 200 μg)缓解AR症状严重程度。方法:采用视觉模拟量表(VAS);在瑞典的常规临床实践中,161名持续性AR (PER)患者在42天的MP-AzeFlu治疗期间使用了0毫米[完全不麻烦]到100毫米[非常麻烦])。患者还评估了他们的睡眠质量。结果:VAS评分在治疗期间较基线下降,患者在第7天之前达到临床相关的VAS评分截止点,89.3%的患者在第1天报告症状良好或部分控制。VAS评分从61.4±22.4 mm(基线)下降到第28天的32.1±24.6 mm和第42天的26.1±24.3 mm(均p < 0.0001),从第42天的基线总体下降38.1±28.2 mm。非常好/良好睡眠质量的患者比例从第0天的3.7%/28.6%上升到第42天的16.5%/51.5%。结论:MP-AzeFlu在瑞典的现实世界临床环境中提供了有效、快速的PER控制。第1天观察到症状改善,持续42天,并与睡眠质量改善相关。MP-AzeFlu显著改善了患者的生活质量,且耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pragmatic and Observational Research
Pragmatic and Observational Research MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
11
期刊介绍: Pragmatic and Observational Research is an international, peer-reviewed, open-access journal that publishes data from studies designed to closely reflect medical interventions in real-world clinical practice, providing insights beyond classical randomized controlled trials (RCTs). While RCTs maximize internal validity for cause-and-effect relationships, they often represent only specific patient groups. This journal aims to complement such studies by providing data that better mirrors real-world patients and the usage of medicines, thus informing guidelines and enhancing the applicability of research findings across diverse patient populations encountered in everyday clinical practice.
期刊最新文献
Improving the Transparency and Replicability of Consensus Methods: Respiratory Medicine as a Case Example. Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy. Comparing Machine Learning and Advanced Methods with Traditional Methods to Generate Weights in Inverse Probability of Treatment Weighting: The INFORM Study. Involvement of Root Canal Treatment in Pro-Inflammatory Processes - A Real-World Study. UK Electronic Healthcare Records for Research: A Scientometric Analysis of Respiratory, Cardiovascular, and COVID-19 Publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1